Thomas Gad
Net Worth

Last updated:

What is Thomas Gad net worth?

The estimated net worth of Mr. Thomas Gad is at least $43,142,910 as of 11 Jun 2024. He owns shares worth $1,387,669 as insider, has earned $37,185,941 from insider trading and has received compensation worth at least $4,569,300 in Y-mAbs Therapeutics, Inc..

What is the salary of Thomas Gad?

Mr. Thomas Gad salary is $761,550 per year as Founder, Chairman, Pres and Head of Bus. Devel. & Strategy in Y-mAbs Therapeutics, Inc..

How old is Thomas Gad?

Mr. Thomas Gad is 55 years old, born in 1970.

What stocks does Thomas Gad currently own?

As insider, Mr. Thomas Gad owns shares in one company:

Company Title Shares Price per share Total value
Y-mAbs Therapeutics, Inc. (YMAB) Founder, Chairman, Pres and Head of Bus. Devel. & Strategy 162,681 $8.53 $1,387,669

What does Y-mAbs Therapeutics, Inc. do?

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

YMAB logo
YMAB
Y-mAbs Therapeutics, Inc.
$8.53

Thomas Gad insider trading

Y-mAbs Therapeutics, Inc.

Mr. Thomas Gad has made 111 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 35,000 units of YMAB stock worth $420,000 on 11 Jun 2024.

The largest trade he's ever made was exercising 150,000 units of YMAB stock on 11 Apr 2019. As of 11 Jun 2024 he still owns at least 162,681 units of YMAB stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 35,000 $12 $420,000
Sale
Common Stock 35,000 $12.03 $421,050
Sale
Common Stock 7,351 $13 $95,563
Sale
Common Stock 25,000 $12 $300,000
Sale
Common Stock 3,900 $16.44 $64,116
Option
Employee Stock Option (right to buy) 50,000 $2 $100,000
Option
Common Stock 50,000 $2 $100,000
Sale
Common Stock 50,000 $6.61 $330,500
Sale
Common Stock 50,000 $6.83 $341,500
Sale
Common Stock 50,000 $6.58 $329,000
Sale
Common Stock 75,000 $5.31 $398,025
Sale
Common Stock 75,000 $5.3 $397,425
Sale
Common Stock 64,276 $6.96 $447,104
Sale
Common Stock 125,863 $7.02 $882,929
Sale
Common Stock 91,031 $7.59 $691,198
Sale
Common Stock 101,104 $7.7 $778,501
Sale
Common Stock 35,060 $7.9 $277,044
Sale
Common Stock 8,000 $10.15 $81,160
Option
Employee Stock Option (right to buy) 8,000 $2 $16,000
Option
Common Stock 8,000 $2 $16,000
Sale
Common Stock 88,055 $10.52 $925,986
Sale
Common Stock 70,318 $10.93 $768,435
Sale
Common Stock 112,767 $11.33 $1,277,312
Option
Employee Stock Option (right to buy) 8,000 $2 $16,000
Sale
Common Stock 69,414 $10.89 $756,127
Option
Common Stock 8,000 $2 $16,000
Sale
Common Stock 8,400 $11.5 $96,600
Sale
Common Stock 10,000 $17.58 $175,830
Sale
Common Stock 44,000 $16.49 $725,516
Sale
Common Stock 25,170 $17.02 $428,343
Sale
Common Stock 22,437 $17.16 $385,019
Option
Common Stock 50,000 $2 $100,000
Option
Employee Stock Option (right to buy) 50,000 $2 $100,000
Sale
Common Stock 50,000 $17.06 $852,850
Sale
Common Stock 4,000 $19.33 $77,304
Sale
Common Stock 4,000 $24.82 $99,260
Sale
Common Stock 4,000 $27.2 $108,800
Sale
Common Stock 4,000 $28.26 $113,056
Sale
Common Stock 4,000 $33.65 $134,580
Option
Common Stock 50,000 $2 $100,000
Option
Employee Stock Option (right to buy) 50,000 $2 $100,000
Sale
Common Stock 50,000 $2 $100,000
Sale
Common Stock 1,779 $28.96 $51,527
Sale
Common Stock 26,111 $29.23 $763,303
Sale
Common Stock 1,110 $31.01 $34,426
Sale
Common Stock 4,000 $33.73 $134,928
Sale
Common Stock 4,000 N/A N/A
Sale
Common Stock 4,000 N/A N/A
Sale
Common Stock 4,000 N/A N/A
Sale
Common Stock 4,000 $35.8 $143,216
Sale
Common Stock 4,000 N/A N/A
Sale
Common Stock 4,000 $34.07 $136,288
Option
Employee Stock Option (right to buy) 7,000 $2 $14,000
Sale
Common Stock 7,000 $2 $14,000
Option
Common Stock 7,000 $2 $14,000
Option
Common Stock 7,000 N/A N/A
Option
Employee Stock Option (right to buy) 7,000 $2 $14,000
Sale
Common Stock 11,000 $14.3 $157,289
Sale
Common Stock 11,000 $14.3 $157,289
Sale
Common Stock 15,000 $1 $15,000
Option
Employee Stock Option (right to buy) 9,000 $2 $18,000
Sale
Common Stock 15,000 $16.14 $242,025
Option
Common Stock 9,000 N/A N/A
Option
Employee Stock Option (right to buy) 7,000 $2 $14,000
Option
Common Stock 7,000 $2 $14,000
Sale
Common Stock 11,000 $19.39 $213,268
Sale
Common Stock 11,000 $18.39 $202,268
Sale
Common Stock 15,000 $18.75 $281,280
Option
Common Stock 9,000 $2 $18,000
Sale
Common Stock 15,000 $18.75 $281,280
Option
Employee Stock Option (right to buy) 9,000 $2 $18,000
Option
Common Stock 7,000 $2 $14,000
Option
Employee Stock Option (right to buy) 7,000 $2 $14,000
Sale
Common Stock 11,000 $24.55 $270,006
Sale
Common Stock 11,000 $21.99 $241,846
Sale
Common Stock 11,000 N/A N/A
Option
Common Stock 7,000 $2 $14,000
Option
Employee Stock Option (right to buy) 7,000 $2 $14,000
Sale
Common Stock 11,000 $24.28 $267,069
Option
Employee Stock Option (right to buy) 7,000 $2 $14,000
Option
Common Stock 7,000 $2 $14,000
Sale
Common Stock 11,000 $24.28 $267,069
Option
Common Stock 7,000 $2 $14,000
Option
Employee Stock Option (right to buy) 7,000 $2 $14,000
Sale
Common Stock 11,000 $25.66 $282,216
Sale
Common Stock 11,000 $25.66 $282,216
Option
Common Stock 7,000 $2 $14,000
Option
Employee Stock Option (right to buy) 7,000 $2 $14,000
Sale
Common Stock 7,000 $2 $14,000
Option
Common Stock 7,000 $2 $14,000
Option
Employee Stock Option (right to buy) 7,000 $2 $14,000
Sale
Common Stock 7,000 $2 $14,000
Sale
Common Stock 4,000 $52.89 $211,544
Sale
Common Stock 50,000 $2 $100,000
Option
Common Stock 50,000 $2 $100,000
Sale
Common Stock 50,000 $2 $100,000
Option
Common Stock 50,000 $2 $100,000
Option
Employee Stock Option (right to buy) 100,000 $1 $100,000
Option
Employee Stock Option (right to buy) 100,000 $2 $200,000
Sale
Common Stock 4,000 $51.42 $205,684
Sale
Common Stock 4,000 $46.17 $184,672
Sale
Common Stock 4,000 $43.69 $174,768
Sale
Common Stock 4,000 $39.15 $156,604
Sale
Common Stock 4,000 $38.88 $155,524
Sale
Common Stock 4,000 $40.81 $163,224
Option
Employee Stock Option (right to buy) 22,569 $41 $925,419
Sale
Common Stock 22,569 $41 $925,419
Option
Common Stock 22,569 $41 $925,419
Option
Common Stock 13,571 $40.33 $547,332
Sale
Common Stock 13,571 $40.33 $547,332
Option
Employee Stock Option (right to buy) 13,571 $40.33 $547,332
Sale
Common Stock 13,860 $2 $27,720
Option
Employee Stock Option (right to buy) 13,860 $2 $27,720
Option
Common Stock 13,860 $2 $27,720
Sale
Common Stock 4,000 $41.6 $166,392
Sale
Common Stock 4,000 $40.35 $161,392
Sale
Common Stock 13,000 $39.51 $513,643
Sale
Common Stock 37,000 $40.06 $1,482,035
Sale
Common Stock 4,000 $36.51 $146,028
Sale
Common Stock 4,000 $40.06 $160,228
Sale
Common Stock 4,000 $42.05 $168,180
Sale
Common Stock 4,000 $43.45 $173,812
Sale
Common Stock 4,000 $41.61 $166,444
Sale
Common Stock 50,000 $39.01 $1,950,450
Sale
Common Stock 4,000 $39.65 $158,596
Sale
Common Stock 50,000 $39.04 $1,951,950
Sale
Common Stock 4,000 $32.35 $129,404
Sale
Common Stock 4,000 $29.43 $117,712
Sale
Common Stock 4,000 $18.01 $72,040
Sale
Common Stock 4,000 $29.18 $116,712
Sale
Common Stock 4,000 $32.78 $131,132
Sale
Common Stock 4,000 $33.03 $132,120
Sale
Common Stock 4,000 $35.06 $140,224
Sale
Common Stock 4,000 $30.9 $123,612
Sale
Common Stock 4,000 $31.54 $126,176
Sale
Common Stock 4,000 $32.48 $129,932
Sale
Common Stock 4,000 $28.41 $113,656
Sale
Common Stock 4,000 $30.11 $120,420
Sale
Common Stock 4,000 $27.59 $110,352
Sale
Common Stock 4,000 $25.21 $100,848
Sale
Common Stock 4,000 $30.59 $122,376
Sale
Common Stock 4,000 $25.77 $103,080
Sale
Common Stock 4,000 $27.7 $110,804
Sale
Common Stock 4,000 $21.78 $87,104
Sale
Common Stock 4,000 $22.54 $90,176
Sale
Common Stock 4,000 $22.4 $89,592
Sale
Common Stock 4,000 $21.77 $87,096
Sale
Common Stock 4,000 $22.79 $91,168
Sale
Common Stock 4,000 $20.03 $80,120
Sale
Common Stock 6,000 $20.21 $121,254
Sale
Common Stock 6,000 $20.61 $123,648
Sale
Common Stock 150,000 $25.8 $3,870,000
Sale
Common Stock 100,000 $26.48 $2,647,600

Y-mAbs Therapeutics key executives

Y-mAbs Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Claus Juan Møller-San Pedro M.D., Ph.D. (62) Chief Executive Officer & Director
  • Mr. Bo Kruse (53) Executive Vice President, Sec., Treasurer & Chief Financial Officer
  • Mr. Thomas Gad (55) Founder, Chairman, Pres and Head of Bus. Devel. & Strategy